Suite 1040 – 885 West Georgia Street
Vancouver, BC V6C 3H1
Tel: 604.336.0881
Email: news@abattis.com

ABATTIS ANNOUNCES NEW DIRECTOR

Vancouver, BC – May 24, 2016 - Abattis Bioceuticals Corp. (the **"Company"** or **"Abattis"**) (OTCQX: ATTBF) (CSE: ATT), is very pleased to announce the appointment of Ms. Maryam Amin Shanjani to the board of directors of the Company as of May 19, 2016.

Ms. Amin Shanjani is a Chartered Professional Accountant, Certified General Accountant and Payroll Compliance Practitioner. She has a BS in Accounting and Business and MS in Economics. Ms. Amin Shanjani joined the Company as Controller in March 2015. In her current role, she is responsible for accounting, financial statements, MD&A, taxation and audit.

Prior to joining the Company, Ms. Amin Shanjani worked for more than ten years as a controller for Canadian and Global public companies at Andover Mining Corp., Chief Consolidated Mining Company, and Digifonica International Inc. Before her roles as Controller, Ms. Amin Shanjani was the System Development Manager for over ten years for Audit Organization in Iran. Managing a staff of 17, she managed the design, implementation and training for financial and cost accounting systems.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Rene David"
Rene David, CFO/COO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are

Suite 1040 – 885 West Georgia Street
Vancouver, BC V6C 3H1
Tel: 604.336.0881
Email: news@abattis.com

based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.